Deciphera Pharmaceuticals, Inc. (DCPH) is a biopharmaceutical company successfully conducting cutting-edge drug discovery in the field of oncology. The company primarily focuses on developing innovative, small molecule drugs to address cancers with persistent and recurrent mutations. Headquartered in Waltham, Massachusetts, USA, Deciphera Pharmaceuticals was founded in 2003 by Dr. Daniel L. Flynn, an experienced medicinal chemist, who has had remarkable success in the field of oncology.
The leading edge of Deciphera Pharmaceuticals is its groundbreaking switch control kinase inhibitor platform, which identifies a switch controlling protein kinase activation. Through this platform, the company has been creating a pipeline of drug candidates designed to improve outcomes for cancer patients.
One of the flagship products that Deciphera Pharmaceuticals has developed is QINLOCK, an inhibitor that has been approved by the FDA. QINLOCK is used for the treatment of adults with advanced GIST (Gastrointestinal Stromal Tumors) who have received prior treatment with three or more kinase inhibitors.
As a biopharmaceutical company, Deciphera Pharmaceuticals, Inc. has shown unwavering commitment to the development of new and advanced treatments for cancer patients. Apart from QINLOCK, Deciphera is tackling multiple oncology indications with its broad pipeline of drug candidates, which include DCC-3014 for advanced solid tumors and inflammatory conditions, rebastinib for breast cancer and solid tumors, as well as other products for lung, skin cancer and other ailments.
A major factor that sets Deciphera apart from other firms in the same industry is its comprehensive approach towards drug discovery and development. Rather than just focusing on symptoms or disease manifestation, the company fervently aims to target the root cause of the disease, allowing for more effective remedies.
Under the leadership of Steve Hoerter, Chief Executive Officer at Deciphera Pharmaceuticals, who has an experience of more than 25 years in the pharmaceutical industry, the company has a vision to transform the lives of cancer patients by addressing key mechanisms of drug resistance in cancer.
Finally, it's important to note DCPH's commitment to its corporate social responsibility. Deciphera Pharmaceuticals, Inc. is devoted to reducing the burden of cancer and ensuring better availability of treatment options for patients across the globe. Their dedication towards ethical business conduct, transparency, and integrity displays their dedication to making the world a better place, beyond their scientific contributions.